Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia

Fineline Cube Aug 12, 2026
Company Deals

Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals

Fineline Cube Aug 12, 2026
Company Deals

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

Fineline Cube Aug 12, 2026
Company Deals

Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia

Fineline Cube Aug 12, 2026
Company Deals

CanSino Biologics Reaches Cooperation Intent With Pakistan’s AGP Limited on PCV13i Pneumococcal Vaccine

Fineline Cube Aug 12, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Fineline Cube Aug 12, 2026
Company Drug

Wantai’s 9‑Valent HPV Vaccine Wins Thailand Approval – China’s First and World’s Second 9vHPV Vaccine Expands Into Southeast Asia

Fineline Cube Aug 12, 2026
Policy / Regulatory

Give Kids a Chance Act Extends FDA Pediatric Research Authority and PRV Program

Fineline Cube Feb 6, 2026

The US Congress has introduced the Give Kids a Chance Act, legislation aimed at broadening...

Company

Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength

Fineline Cube Feb 5, 2026

Eli Lilly and Company (NYSE: LLY) reported fourth‑quarter 2025 revenue of USD 19.29 billion, up 43% year‑on‑year (YOY),...

Company

Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion

Fineline Cube Feb 5, 2026

Novartis AG (NYSE: NVS) reported full‑year 2025 net sales of USD 54.5 billion, up 8% year‑on‑year (YOY) at...

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026

Everest Medicines Limited (HKG: 1952) announced a licensing agreement with Micot, a polypeptide NME drug...

Company Medical Device

GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength

Fineline Cube Feb 5, 2026

GE HealthCare (NASDAQ: GEHC) reported fourth‑quarter 2025 revenue of USD 5.7 billion, up 7.1% year‑on‑year (YOY), bringing full‑year...

Company Deals

MediTrust Mabwell Insurance Ecosystem Partnership

Fineline Cube Feb 5, 2026

Shanghai MediTrust Health Technology Group Co., Ltd. (a subsidiary of Shanghai Pharmaceuticals) announced a comprehensive...

Company Drug

Hanx Biopharma HX111 ADC Begins Phase I Trial for Lymphoma and Solid Tumors

Fineline Cube Feb 5, 2026

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced the initiation of a Phase I clinical...

Company Deals

Pfizer Launches Migraine Management Zone at China Pharmacy

Fineline Cube Feb 5, 2026

Pfizer Inc. (NYSE: PFE) in collaboration with GuoDa Drugstore Co., Ltd. (part of Sinopharm) this week...

Company Drug

Shouyao’s SY-9453 MAT2A Inhibitor Gets NMPA Nod for MTAP-Deleted Tumors

Fineline Cube Feb 5, 2026

Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197) announced that the National Medical Products Administration (NMPA)...

Company

Innovent Biologics Revenue Surges 45% on Oncology Portfolio Expansion

Fineline Cube Feb 5, 2026

Innovent Biologics, Inc. (HKG: 1801) reported strong financial results for Q4 and full‑year 2025, with total...

Company Drug

Huadong Medicine DR10624 Gets NMPA Nod for Hypertriglyceridemia Study

Fineline Cube Feb 5, 2026

Huadong Medicine Co., Ltd (SHE: 000963) announced that its subsidiary Doer Biologics has received National...

Company Deals

Takeda Ends $128M Kyoto University iPSC Project After Decade of Research

Fineline Cube Feb 5, 2026

Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced the termination of its ten‑year induced pluripotent stem cell (iPSC)...

Hospital Policy / Regulatory

Beijing Online Consultation Pilot Gets NHC Approval for Children’s Care

Fineline Cube Feb 5, 2026

China’s National Health Commission (NHC) has approved the “Standardized Pilot Program for Online Initial Consultations...

Company Drug

AstraZeneca Saphnelo Faces FDA Setback with Complete Response Letter

Fineline Cube Feb 5, 2026

AstraZeneca (AZ, NASDAQ: AZN) announced it has received a Complete Response Letter (CRL) from the U.S....

Company

AbbVie Immunology Portfolio Drives $61.2B Revenue in 2025

Fineline Cube Feb 5, 2026

AbbVie Inc. (NYSE: ABBV) reported fourth‑quarter revenue of USD 16.618 billion, up 9.5% year‑on‑year (YOY), bringing full‑year 2025...

Company Deals Digital

Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System

Fineline Cube Feb 5, 2026

Mirxes Singapore (HKG: 2629) announced a partnership with XtalPi Inc. (QuantumPharm, HKG: 2228) and its...

Company Deals

Lishan Biopharma Licenses Evogene’s LS-LBP-002 for Global Oncology Development

Fineline Cube Feb 5, 2026

Shanghai Lishan Biopharmaceuticals Co., Ltd. announced a licensing agreement with Israel‑based Evogene Ltd. (NASDAQ: EVGN) for...

Company

Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows

Fineline Cube Feb 4, 2026

Pfizer Inc. (NYSE: PFE) reported full‑year 2025 revenue of USD 62.6 billion, representing a 2% operational decline at constant...

Others

Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump

Fineline Cube Feb 4, 2026

Merck & Co. (MSD, NYSE: MRK) reported full‑year 2025 revenue of USD 65.5 billion, up 2% year‑on‑year...

Company Drug

Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial

Fineline Cube Feb 4, 2026

Hualan Biological Engineering Inc. (SHE: 002007) announced that the National Medical Products Administration (NMPA) has...

Posts pagination

1 … 87 88 89 … 707

Recent updates

  • Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026
  • Haohai Wins NMPA Approval for China’s First Domestic Trifocal Toric Intraocular Lens for Cataract Patients With Astigmatism
  • Wantai’s 9‑Valent HPV Vaccine Wins Thailand Approval – China’s First and World’s Second 9vHPV Vaccine Expands Into Southeast Asia
  • Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia
  • MSD Signs Oncology Collaboration With InventisBio Through MCICC to Accelerate Small‑Molecule Clinical Development
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Company Medical Device

Haohai Wins NMPA Approval for China’s First Domestic Trifocal Toric Intraocular Lens for Cataract Patients With Astigmatism

Company Drug

Wantai’s 9‑Valent HPV Vaccine Wins Thailand Approval – China’s First and World’s Second 9vHPV Vaccine Expands Into Southeast Asia

Company Deals

Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.